Bristol Says Ruling Shields Eliquis From Generics Until 2028

Sept. 3, 2021, 3:47 PM

Bristol-Myers Squibb Co. won an appeals court ruling upholding the validity of two patents for the blockbuster blood-thinner Eliquis, which the company said closes the door on all copycat versions until 2028.

In a one-paragraph opinion, the U.S. Court of Appeals for the Federal Circuit affirmed a trial court’s “thorough and thoughtful” ruling that prevents three generic-drug makers from entering the market until both patents expire. The court issued its decision just one day after hearing arguments in the case.

Eliquis is Bristol-Myers’ second biggest money-maker behind the multiple myeloma drug Revlimid. The blood-thinner generated more than $3.6 billion in ...

To read the full article log in.

Learn more about a Bloomberg Law subscription